Skip navigation
Skip navigation

The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors

Stuart-Harris, Robin; Shadbolt, Bruce; Palmqvist, C; Ross, H.A Chaudri

Description

We analysed the outcomes of women with metastatic breast cancer (MBC) from three randomised phase III trials of aromatase inhibitors according to oestrogen receptor (ER) and progesterone receptor (PgR) status. Both receptors were analysed in 1010 of the 1870 women (54%), including 31 that were ER-/PgR-, which were excluded. Of the remaining 979, 726 (74%) were ER+/PgR+ but 253 were single hormone receptor positive (213 ER+/PgR-, 40 ER-/PgR+). Although there were no differences in clinical...[Show more]

dc.contributor.authorStuart-Harris, Robin
dc.contributor.authorShadbolt, Bruce
dc.contributor.authorPalmqvist, C
dc.contributor.authorRoss, H.A Chaudri
dc.date.accessioned2015-12-08T22:27:15Z
dc.identifier.issn0960-9776
dc.identifier.urihttp://hdl.handle.net/1885/33998
dc.description.abstractWe analysed the outcomes of women with metastatic breast cancer (MBC) from three randomised phase III trials of aromatase inhibitors according to oestrogen receptor (ER) and progesterone receptor (PgR) status. Both receptors were analysed in 1010 of the 1870 women (54%), including 31 that were ER-/PgR-, which were excluded. Of the remaining 979, 726 (74%) were ER+/PgR+ but 253 were single hormone receptor positive (213 ER+/PgR-, 40 ER-/PgR+). Although there were no differences in clinical benefit or time to progression, the median overall survival of women with ER+/PgR+ tumours was significantly longer than those with single HR positive tumours (800 versus 600 days, p = 0·01). In women with ER+ tumours, the median overall survival of those with tumours that were also PgR+ was significantly longer than those that were PgR- (800 versus 625 days, p = 0·02). The PgR status is an important prognostic factor for survival in MBC.
dc.publisherChurchill Livingstone
dc.sourceThe Breast
dc.subjectKeywords: aminoglutethimide; anastrozole; estrogen receptor; letrozole; megestrol acetate; progesterone receptor; article; breast cancer; clinical trial; controlled clinical trial; human; overall survival; priority journal; prognosis; randomized controlled trial; s ER; Estrogen receptor; Metastatic breast cancer; PgR; Progesterone receptor; Survival
dc.titleThe prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors
dc.typeJournal article
local.description.notesImported from ARIES
local.identifier.citationvolume18
dc.date.issued2009
local.identifier.absfor111205 - Chemotherapy
local.identifier.ariespublicationu4201517xPUB108
local.type.statusPublished Version
local.contributor.affiliationStuart-Harris, Robin, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationShadbolt, Bruce, Canberra Hospital
local.contributor.affiliationPalmqvist, C, Canberra Hospital
local.contributor.affiliationRoss, H.A Chaudri, Novartis Pharma AG
local.description.embargo2037-12-31
local.bibliographicCitation.issue6
local.bibliographicCitation.startpage351
local.bibliographicCitation.lastpage355
local.identifier.doi10.1016/j.breast.2009.09.002
dc.date.updated2016-02-24T10:40:26Z
local.identifier.scopusID2-s2.0-71749114406
CollectionsANU Research Publications

Download

File Description SizeFormat Image
01_Stuart-Harris_The_prognostic_significance_of_2009.pdf275.07 kBAdobe PDF    Request a copy
02_Stuart-Harris_The_prognostic_significance_of_2009.pdf271.53 kBAdobe PDF    Request a copy


Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator